Denna sida på svenska
Loading profile information...

About me

Head of Grants Office at Karolinska Institutet.

I am leading a unit with highly qualified staff that represent a strong mix of capabilities within scientific research and administration, scientific writing, communication and knowledge within the domains of the European Union and other international and national funding bodies.
Working in the borderland of academia and life science industry I have over the years gained a deep knowledge in the various national and European funding programs.

Over the past 15 years, I have work in, and in support of, innovation driven research and its financing. I graduated 1994 in Molecular Pharmacology at the University of Lund followed by postgraduate training 1995-2000 at Karolinska Institutet where I received a doctorate degree in Neuropharmacology. After two years post-doc supported by the Swedish Brain foundation, I joined Biovitrum AB where I worked 2003-2005 with target validation and assay development. In 2005-2012 I worked for Actar AB where main responsibilities included in-licensing evaluation and due diligence of research projects, management and research strategy. Other major duties included project evaluation and planning, infrastructure build-up and recruitment. At SwedenBIO my main tasks was to to help Swedish Life Science SMEs obtain funding from the EU's Framework Program (FP7) for Research and Technological Development, providing information, advice and to identify relevant calls.

Specialties: Drug Discovery and development in the pharmaceutical industry; Target validation and assay development, soft money, funding, grant applications, EU's Framework Program (FP7) and Horizon 2020.


Karolinska InstitutetPh.D. received 10:th of March 2000 in Pharmacology

University of LundMaster of Science in Mathematic and Nature science 1989-1993

Research description

Grants Office is part of the Faculty Office and International Relations at the Karolinska Institutet university administration. Our personnel represent a strong mix of capabilities within scientific research and administration, scientific writing, communication and knowledge within the domains of the European Union and other international and national funding bodies.
Grants Office supports researchers at Karolinska Institutet with guidance and advice throughout the complete process of finding and applying for external research funding up until final closure of the project.
We focus on funding from European and US sponsors such as the NIH as well as national and Nordic sponsors in larger calls for proposals. Grants Office communicates information from sponsors and identifies future trends in science and intentions of funding organisations.


Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell Ag, et al
Nature biotechnology 2012;30(3):283-8

A facilitated approach to evaluate the inhibitor mode and potency of compounds targeting microsomal prostaglandin e synthase-1
Spahiu L, Stenberg P, Larsson C, Wannberg J, Alterman M, Kull B, et al
Assay and drug development technologies 2011;9(5):487-95

Evidence against adenosine analogues being agonists at the growth hormone secretagogue receptor
Johansson S, Fredholm Bb, Hjort C, Morein T, Kull B, Hu Ps
Biochemical pharmacology 2005;70(4):598-605

Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function
Ding B, Kull B, Liu Z, Mottagui-tabar S, Thonberg H, Gu Hf, et al
Regulatory peptides 2005;127(1-3):45-53

A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex?
Isacson R, Kull B, Wahlestedt C, Salmi P
Neuroscience 2004;124(1):33-42

Dihydrexidine--the first full dopamine D1 receptor agonist
Salmi P, Isacson R, Kull B
CNS drug reviews 2004;10(3):230-42

Lack of efficacy of 'naked' small interfering RNA applied directly to rat brain
Isacson R, Kull B, Salmi P, Wahlestedt C
Acta physiologica Scandinavica 2003;179(2):173-7

Adenosine A(2A) receptor facilitation of hippocampal synaptic transmission is dependent on tonic A(1) receptor inhibition
Lopes Lv, Cunha Ra, Kull B, Fredholm Bb, Ribeiro Ja
NEUROSCIENCE 2002;112(2):319-29

Anoxia redistributes adenosine A(2A) receptors in PC12 cells and increases receptor-mediated formation of cAMP
Arslan G, Kull B, Fredholm Bb
Naunyn-Schmiedeberg's archives of pharmacology 2002;365(2):150-7

Adenosine receptor signaling in vitro and in vivo
Fredholm Bb, Arslan G, Halldner L, Kull B, Schulte G, Aden U, et al
DRUG DEVELOPMENT RESEARCH 2001;52(1-2):274-282

Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells
Fredholm Bb, Irenius E, Kull B, Schulte G
Biochemical pharmacology 2001;61(4):443-8

Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum
Kull B, Svenningsson P, Fredholm Bb
Molecular pharmacology 2000;58(4):771-7

GTP differentially affects antagonist radioligand binding to adenosine A(1) and A(2A) receptors in human brain
Kull B, Svenningsson P, Hall H, Fredholm Bb
Neuropharmacology 2000;39(12):2374-80

P2Y receptors contribute to ATP-induced increases in intracellular calcium in differentiated but not undifferentiated PC12 cells
Arslan G, Filipeanu Cm, Irenius E, Kull B, Clementi E, Allgaier C, et al
Neuropharmacology 2000;39(3):482-96

Structure and function of adenosine receptors and their genes
Fredholm Bb, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W
Naunyn-Schmiedeberg's archives of pharmacology 2000;362(4-5):364-74

Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors
Kull B, Arslan G, Nilsson C, Owman C, Lorenzen A, Schwabe U, et al
Biochemical pharmacology 1999;57(1):65-75

Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors
Kull B, Ferré S, Arslan G, Svenningsson P, Fuxe K, Owman C, et al
Biochemical pharmacology 1999;58(6):1035-45

Signaling via A2A adenosine receptor in four PC12 cell clones
Arslan G, Kull B, Fredholm Bb
Naunyn-Schmiedeberg's archives of pharmacology 1999;359(1):28-32

Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells
Klotz Kn, Hessling J, Hegler J, Owman C, Kull B, Fredholm Bb, et al

Locating the neuronal targets for caffeine
Fredholm Bb, Arslan G, Kull B, Svenningsson P
DRUG DEVELOPMENT RESEARCH 1998;45(3-4):324-328

Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas
Svenningsson P, Le Moine C, Kull B, Sunahara R, Bloch B, Fredholm Bb
Neuroscience 1997;80(4):1171-85

Characterization of human A(2A) adenosine receptors with the antagonist radioligand [H-3]-SCH 58261
Dionisotti S, Ongini E, Zocchi C, Kull B, Arslan G, Fredholm Bb

Localization of adenosine receptor messenger RNAs in the rat eye
Kvanta A, Seregard S, Sejersen S, Kull B, Fredholm Bb
Experimental eye research 1997;65(5):595-602

Adenosine A2A receptors modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells
Dasgupta S, Ferré S, Kull B, Hedlund Pb, Finnman Ub, Ahlberg S, et al
European journal of pharmacology 1996;316(2-3):325-31

Adenosine (P1) receptor signalling
Fredholm Bb, Arslan C, Kull B, Kontny E, Svenningsson P
DRUG DEVELOPMENT RESEARCH 1996;39(3-4):262-268

P2x purinoceptor is not important in thymocyte apoptosis
Jiang S, Kull B, Fredholm Bb, Orrenius S
Immunology letters 1996;49(3):197-201

Show all publications


View map

Nobels väg 15A